• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Schering-Plough Corporation - Articles and news items

Merck logo

Merck appoints Michael J. Holston as Chief Ethics and Compliance Officer

Industry news, News / 28 March 2012 / Merck

Long-time Merck and Schering-Plough Executive Richard S. Bowles to retire…

In vitro toxicity screening as pre-selection tool

Issue 3 2008, Past issues / 19 June 2008 /

Drug discovery relies on massive screening of compound libraries with in vitro cell-based target assays. These pharmacological screens have been well accepted. For in vitro toxicological screening, this privilege has only been obtained for the Ames, chromosomal aberration and eye irritation tests. At the moment, a number of cellular assays for cytotoxicity, genotoxicity, embryotoxicity, cellular metabolic activation processes and endocrine disruption await general acceptance. From that point onwards, tools will become available to identify unwanted pharmacological or toxicological effects at a much earlier stage in the drug development process.

Ten steps to success

Issue 2 2005, Past issues / 20 May 2005 / Dr Christopher Haas, Senior Director Pharmaceutical Technology, Schering Plough Corporation

The technology transfer management process reflects an integrated approach to the best practices benchmarked.

A well-defined and well-designed technology transfer process is critical for ensuring successful commercial launch. Technology transfer includes manufacturing, packaging and test method transfer to commercial sites.


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +